Skip to main content

Table 1 Characteristics of the main phase III adjuvant trials in high-risk melanoma patients.

From: Adjuvant therapy of melanoma with interferon: lessons of the past decade

References

Intergroup Trial

AJCC Stage

# Total Patients enrolled

Arms

# Patients for arm

RFS

P value

OS

P value

Creagan et al. (1995)54

NCCTG 83–7052

II–III

262

2

HDI 131

Control 131

0.19

0.40

Kirkwood et al. (1996)1

ECOG E1684

IIB–III

287

2

HDI 143

Control 137

0.0023

0.0237

Grob et al. (1998)34

French CGM

IIAB

499

2

LDI 253

Control 246

0.035

0.059

Pehamberger et al.(1998)58

Austrian MMCG

IIAB

311

2

LDI 154

Control 157

0.02

n.d

Kirkwood et al. (2000)25

ECOG-US Intergroup E1690

IIB–III

642

3

HDI 203

LDI 203

Control 202

0.03*

0.17**

0.744*

0.672**

Kirkwood et al. (2001)26

ECOG-US Intergroup

E1694

IIB–III

774

2

HDI 385

GM2/QS-21 389

0.006

0.04

Cascinelli et al. (2001)59

WHO 16

III

444

2

LDI 218

Control 208

0.50

0.72

Cameron et al. (2001)60

Scottish MG

II–III

96

2

LDI 47

Control 49

> 0.1

> 0.2

Hancock et al. (2004)61

UKCCCR-MCG

IIB–III

654

2

LDI 338

Control 336

0.3

0.6

Kleeberg et al. (2004)62

EORTC 18871

II–III

423

3

UDI 240

IFNγ 244

Control 244

0.71°

0.73°°

0.72°

0.25°°

Kleeberg et al. (2004)62

DKG-80

II–III

407

4

Iscador 102

Control 102

0.12

0.31

Eggermont et al. (2005)31

EORTC 18952

IIB–III

1418

3

HID-IFN 565

LID-IFN 569

Control 284

0.1*

0.2*

Eggermont et al. (2008)32

EORTC 18991

III

1256

2

PEG-IFN 627

Control 629

0.011#

0.107##

0.78

Gogas et al. (2007)33

He.Co.G

IIBC–III

364

2

HDI 1 mos 182

HDI 12 mos 182

0.94

0.51

  1. RFS: Relapse-free survival; OS: Overall survival; HDI: high-dose interferon; ULD-IFN: Ultra-low dose interferon; HID-IFN: high-intermediate dose interferon; LID-IFN: low-intermediate dose interferon. P value refers to comparison between HDI and control groups* or LDI and control**. P value refers to comparison between LID-IFN and control and reflects the Distant Metastases Free Survival (DMFS)*. P value refers to comparison between UDI and control° or IFNγ and control°°. P value refers to Relapse-Free Survival# and DMFS##.